Characterization of a folate transporter in HeLa cells with a low pH optimum and high affinity for pemetrexed distinct from the reduced folate carrier

Clinical Cancer Research

Volumn 10, Issue 18 I, 2004, Pages 6256-6264

  Wang, Yanhua ^a   Zhao, Rongbao ^a   Goldman, I David ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDEAZATETRAHYDROFOLIC ACID; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID; FOLIC ACID ANTAGONIST; FOLINIC ACID; METHOTREXATE; NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE; PEMETREXED; PLEVITREXED; PT 632; RALTITREXED; REDUCED FOLATE CARRIER; TETRAHYDROFOLIC ACID DERIVATIVE; TRIMETREXATE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL PH; CONTROLLED STUDY; DRUG PROTEIN BINDING; HELA CELL; HUMAN; HUMAN CELL; ISOMER; PRIORITY JOURNAL; PROTON TRANSPORT; STEREOSPECIFICITY;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; BLOTTING, NORTHERN; CARRIER PROTEINS; CELL LINE; CELL LINE, TUMOR; FOLIC ACID; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; IONS; KINETICS; MEMBRANE TRANSPORT PROTEINS; METHOTREXATE; PROTEIN ISOFORMS; QUINAZOLINES; RECEPTORS, CELL SURFACE; RNA; THIOPHENES; TIME FACTORS; TRANSFECTION; TRIMETREXATE;

EID: 4644224936     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0645     Document Type: Article

References (44)

1. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003;66:403-56.
2. Sierra EE, Brigle KE, Spinella MJ, Goldman ID. pH dependence of methotrexate transport by the reduced folate carrier and the folate receptor in L1210 leukemia cells. Further evidence for a third route mediated at low pH. Biochem Pharmacol 1997;53:223-31.
3. Vincent ML, Russell RM, Sasak V. Folic acid uptake characteristics of a human colon carcinoma cell line, Caco-2. A newly-described cellular model for small intestinal epithelium. Hum Nutr Clin Nutr 1985;39:355-60.
4. Henderson GB, Strauss BP. Characteristics of a novel transport system for folate compounds in wild-type and methotrexate-resistant L1210 cells. Cancer Res 1990;50:1709-14.
5. Kuhnel JM, Chiao JH, Sirotnak FM. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells. J Cell Physiol 2000;184:364-72.
6. Horne DW, Reed KA. Transport of methotrexate into PC-3 human prostate cancer cells. Arch Biochem Biophys 2001;394:39-44.
7. Chancy CD, Kekuda R, Huang W, et al. Expression and differential polarization of the reduced-folate transporter-1 and the folate receptor alpha in mammalian retinal pigment epithelium. J Biol Chem 2000;275:20676-84.
8. Assaraf YG, Babani S, Goldman ID. Increased activity of a novel low pH folate transporter associated with lipoplilic antifolate resistance in Chinese hamster ovary cells. J Biol Chem 1998;273:8106-11.
9. Zhao R, Gao F, Hanscom M, Goldman ID. A prominent low pH methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in HeLa cells lacking the reduced folate carrier. Clin Cancer Res 2004;10:718-27.
10. Selhub J, Dhar GJ, Rosenberg IH. Gastrointestinal absorption of folates and antifolates. Pharmacol Ther 1983;20:397-418.
11. Rajgopal A, Sierra EE, Zhao R, Goldman ID. Expression of the reduced folate carrier SLC19A1 in IEC-6 cells results in two distinct transport activities. Am J Physiol Cell Physiol 2001;281:C1579-86.
12. Chiao JH, Roy K, Tolner B, Yang CH, Sirotnak FM. RFC-1 gene expression regulates folate absorption in mouse small intestine. J Biol Chem 1997;272:11165-70.
13. Kumar CK, Nguyen TT, Gonzales FB, Said HM. Comparison of intestinal folate carrier clone expressed in IEC-6 cells and in Xenopus oocytes. Am J Physiol 1998;274:C289-94.
14. Said HM, Chatterjee N, Haq RU, et al. Adaptive regulation of intestinal folate uptake: effect of dietary folate deficiency. Am J Physiol Cell Physiol 2000;279:C1889-95.
15. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyrrolo[2,3-D]pyrimidine- based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-23.
16. Fry DW, Yalowich JC, Goldman ID. Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J Biol Chem 1982;257:1890-6.
17. Wang Y, Zhao R, Chattopadhyay S, Goldman ID. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res 2002;62:6434-7.
18. Wang Y, Zhao R, Chattopadhyay S, Goldman ID. Correction. Cancer Res 2003;63:7004.
19. Sharif KA, Goldman ID. Rapid determination of membrane transport parameters in adherent cells. BioTechniques 2000;28:926-8, 930-2.
20. Wong SC, Zhang L, Proefke SA, Matherly LH. Effects of the loss of capacity for N-glycosylation on the transport activity and cellular localization of the human reduced folate carrier. Biochim Biophys Acta 1998;1375:6-12.
21. Bowen D, Diasio RB, Goldman ID. Distinguishing between membrane transport and intracellular metabolism of fluorodeoxyuridine in Ehrlich ascites tumor cells by application of kinetic and high performance liquid Chromatographic techniques. J Biol Chem 1979;254:5333-9.
22. Lowe AG, Walmsley AR. The kinetics of glucose transport in human red blood cells. Biochim Biophys Acta 1986;857:146-54.
23. Goldman ID. A model system for the study of heteroexchange diffusion: methotrexate-folate interactions in L1210 leukemia and Ehrlich ascites tumor cells. Biochim Biophys Acta 1971;233:624-34.
24. Goldman ID. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann N Y Acad Sci 1971;186:400-22.
25. Henderson GB, Zevely EM. Structural requirements for anion substrates of the methotrexate transport system of L1210 cells. Arch Biochem Biophys 1983;221:438-46.
26. Henderson GB, Zevely EM. Functional correlations between the methotrexate and general anion transport systems of L1210 cells. Biochem Int 1982;4:493-502.
27. Henderson GB, Zevely EM. Use of non-physiological buffer systems in the analysis of methotrexate transport in L1210 cells. Biochem Int 1983;6:507-15.
28. Goldman ID. Transport energetics of the folic acid analogue, methotrexate, in L1210 cells: enhanced accumulation by metabolic inhibitors. J Biol Chem 1969;244:3779-85.
29. Saier MH Jr, Beatty JT, Goffeau A, et al. The major facilitator superfamily. J Mol Microbiol Biotechnol 1999;1:257-79.
30. Westerhof GR, Schornagel JH, Kathmann I, et al. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular- structure and biological activity. Mol Pharmacol 1995;48:459-71.
31. Zhao R, Babani S, Gao F, Liu L, Goldman ID. The mechanism of transport of the multitargeted antifolate, MTA-LY231514, and its cross resistance pattern in cell with impaired transport of methotrexate. Clin Cancer Res 2000;6:3687-95.
32. Schron CM, Washington C Jr, Blitzer BL. The transmembrane pH gradient drives uphill folate transport in rabbit jejunum. Direct evidence for folate/hydroxyl exchange in brush border membrane vesicles. J Clin Investig 1985;76:2030-3.
33. Zhao R, Gao F, Wang Y, et al. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 2000;276:1114-8.
34. Zhao R, Gao F, Goldman ID. Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am J Physiol Cell Physiol 2002;282:C1512-7.
35. Dutta B, Huang W, Molero M, et al. Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem 1999;274:31925-9.
36. Rajgopal A, Edmondson A, Goldman ID, Zhao R. SLC19A3 encodes a second thiamine transporter, ThTr2. Biochim Biophys Acta 2001;1537:175-8.
37. Zhao R, Hanscom M, Chattopadhyay S, Goldman ID. Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier; association with the presence of a secondary transport pathway. Cancer Res 2004;64:3313-9.
38. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001;61:857-65.
39. Poe M. Acidic dissociation constants of folic acid, dihydrofolic acid, and methotrexate. J Biol Chem 1977;252:3724-8.
40. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
41. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
42. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984;2:343-66.
43. 2 gradients in solid tumors in vivo: high- resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-82.
44. 31P magnetic resonance spectroscopy. Biochem Pharmacol 1999;57:309-12.